Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biofrontera AGLTS:0DOL 6 3-Year EBITDA Growth Rate is 81.90% as of Mar. 2026, which is 566% above its 10-year median of 12.30. GuruFocus rates LTS:0DOL with a GF Score™ of 6/100 and a GF Value™ of €2.35 (Fairly Valued). The stock has 4 warning signs investors should review. Among 809 Drug Manufacturers companies, Biofrontera AG ranks better than 96.17% on this metric.
During the past 12 months, Biofrontera AG's average EBITDA Per Share Growth Rate was -124.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 81.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Biofrontera AG was 81.90% per year. The lowest was -51.60% per year. And the median was 12.30% per year.
Biofrontera AG (LTS:0DOL) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Biofrontera AG 3-Year EBITDA Growth Rate Related Terms
LTS:0DOL vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera AG 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Biofrontera AG's 3-Year EBITDA Growth Rate falls into.
Biofrontera AG 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 81.90% mean?
Biofrontera AG (LTS:0DOL) has a 3-Year EBITDA Growth Rate of 81.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Biofrontera AG and its competitors. This is 566% above median its historical median of 12.30. According to the industry distribution chart, Biofrontera AG ranks #31 out of 809 companies in the Drug Manufacturers industry, placing it in the top 3.8%.
Is Biofrontera AG's 3-Year EBITDA Growth Rate too high?
Biofrontera AG's current 3-Year EBITDA Growth Rate of 81.90% is 566% above median its 10-year median of 12.30. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Biofrontera AG's value of 81.90% is 820.2% above this industry median. Based on the distribution chart, Biofrontera AG ranks #31 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biofrontera AG has a GF Score™ of 6/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofrontera AG ranks #31 out of 809 companies for 3-Year EBITDA Growth Rate. This places Biofrontera AG in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Biofrontera AG's value of 81.90% is 820.2% above this benchmark. While the company's 10-year median is 12.30 vs. the industry median of 8.90, Biofrontera AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofrontera AG's current 3-Year EBITDA Growth Rate of 81.90% is 820.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Biofrontera AG and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofrontera AG's current 3-Year EBITDA Growth Rate is 81.90%, which is 566% above median its own 10-year median of 12.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera AG (LTS:0DOL) is currently considered Fairly Valued. The stock's GF Value™ is €2.35, compared to a current price of €2.53 — trading 7.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 81.90%, which is 566% above median its 10-year median of 12.30 and 820.2% above the Drug Manufacturers industry median of 8.90. Biofrontera AG's overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Biofrontera AG (LTS:0DOL), the current 3-Year EBITDA Growth Rate is 81.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera AG (LTS:0DOL) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera AG stock appears to be overvalued.
The current stock price of €2.53 is trading 7.7% above its estimated GF Value™ of €2.35.
GuruFocus considers Biofrontera AG to be Fairly Valued.
Key valuation signals for LTS:0DOL:
3-Year EBITDA Growth Rate: 81.90% (566% above median its 10-year median of 12.30)
GF Value™: €2.35 vs. price of €2.53 (7.7% above fair value)
Industry Position: 820.2% above the Drug Manufacturers median (#31 of 809)
No single metric tells the full story. See the LTS:0DOL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
6GF Score
Get the complete analysis for LTS:0DOL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DOL has been successfully added to your 
